LAVAL, Quebec, Nov. 2, 2017 /PRNewswire/ -- Ortho
Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that the U.S.
Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and
tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018.
If approved, IDP-118 will be the first and only topical lotion that contains a unique combination of halobetasol
propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially
expanded duration of use.
The most common adverse events were contact dermatitis (7.4%) and application site pain (2.6%).
About Ortho Dermatologics
Ortho Dermatologics, aValeant Pharmaceuticals International, Inc. company , is one of the largest
prescription dermatology companies in the world dedicated to helping patients in the treatment of a range of therapeutic areas
including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus and other dermatoses.
The Ortho Dermatologics portfolio includes several leading acne, anti-fungal and anti-infective products. More information can be
found at www.ortho-dermatologics.com.
About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that
develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology,
gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found
at www.valeant.com.
Forward-looking Statements
This press release may contain forward-looking statements which may generally be identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential,"
"target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and
beliefs of the management of Valeant and Nicox and are subject to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in Valeant's most recent annual or quarterly report and detailed from time to time
in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors
are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the date hereof. Neither Valeant nor Nicox undertakes any
obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press
release or to reflect actual outcomes, unless required by law.
View original content with multimedia:http://www.prnewswire.com/news-releases/ortho-dermatologics-announces-us-fda-filing-acceptance-for-idp-118-novel-plaque-psoriasis-treatment-300548118.html
SOURCE Valeant Pharmaceuticals International, Inc.